Globeflex Capital L P Acquires New Shares in DaVita Inc. $DVA

Globeflex Capital L P acquired a new position in shares of DaVita Inc. (NYSE:DVA) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,451 shares of the company’s stock, valued at approximately $3,438,000.

A number of other institutional investors and hedge funds have also bought and sold shares of DVA. Value Investment Professionals LLC boosted its stake in shares of DaVita by 2.0% during the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after purchasing an additional 50 shares in the last quarter. Kesler Norman & Wride LLC grew its holdings in shares of DaVita by 0.8% during the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after purchasing an additional 55 shares during the last quarter. Gen Wealth Partners Inc increased its stake in shares of DaVita by 10.0% in the fourth quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after buying an additional 80 shares during the period. NewEdge Advisors LLC raised its holdings in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the last quarter. Finally, Orion Porfolio Solutions LLC boosted its position in DaVita by 4.4% during the 4th quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock worth $268,000 after buying an additional 99 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insiders Place Their Bets

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.90% of the stock is owned by corporate insiders.

DaVita Stock Performance

NYSE:DVA opened at $174.21 on Monday. The company has a market capitalization of $11.11 billion, a PE ratio of 14.26, a P/E/G ratio of 0.58 and a beta of 0.88. The company has a 50 day simple moving average of $214.96 and a two-hundred day simple moving average of $182.03. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same quarter in the previous year, the company earned $2.95 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts predict that DaVita Inc. will post 14.57 EPS for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of a number of research reports. Oppenheimer set a $220.00 target price on shares of DaVita in a report on Friday, August 7th. Barclays lifted their price target on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Truist Financial reduced their price objective on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $221.75.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.